Researchers conducted a randomized controlled trial to see how different vaccine schedules affect the immune response to the Human Papillomavirus (HPV). The study involved 337 boys and girls between the ages of 9 and 10. They compared a mixed schedule, which used one dose of a nonavalent vaccine and one dose of a bivalent vaccine, against a standard two-dose nonavalent vaccine schedule.
The results showed that the mixed schedule successfully produced detectable antibodies for all targeted HPV types. Specifically, the mixed schedule led to significantly higher geometric mean concentrations of antibodies for HPV types 16 and 18 compared to the standard two-dose nonavalent schedule. These two types are major targets for the vaccines.
While the results suggest that a mixed schedule is a feasible way to build immunity, the study did not measure how well these vaccines work in real-world clinical practice. Because the study did not report on side effects or long-term clinical outcomes, these findings are currently used to support the feasibility of the schedule rather than to change immediate medical policy.
